APB A002
Alternative Names: A-002 - APITBIO; APB-A-002Latest Information Update: 12 Dec 2022
At a glance
- Originator APITBIO
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immune checkpoint protein inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Solid tumours
Most Recent Events
- 02 Dec 2022 Early research in Solid tumours in South Korea (Parenteral) prior to December 2022.